|
@@ -48,31 +48,47 @@ A graft is categorized based on the relationship between donor and recipient:
|
|
|
|
|
|
:::
|
|
|
|
|
|
-## Allograft rejection is a major long-term problem
|
|
|
+## Recipient T-cells reject allogenic MHCs
|
|
|
|
|
|
-![Kidney allograft survival rates in children by transplant year[^kim-marks]](graphics/presentation/kidney-graft-survival.png){ height=65% }
|
|
|
+::::: {.columns}
|
|
|
|
|
|
-[^kim-marks]:[ Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/?report=classic)
|
|
|
+::: {.column width="75%"}
|
|
|
|
|
|
-## Graft rejection is an adaptive immune response
|
|
|
+:::: incremental
|
|
|
|
|
|
-<!-- TODO: Need a graphic for this -->
|
|
|
+<!-- Vertical alignment hacks -->
|
|
|
|
|
|
-::: incremental
|
|
|
+\rule{\linewidth}{0pt}
|
|
|
+
|
|
|
+\vspace*{36pt}
|
|
|
|
|
|
-* The host's adaptive immune system identifies and attacks cells
|
|
|
- bearing non-self antigens
|
|
|
+* TCR binds to both antigen *and* MHC surface \vspace{10pt}
|
|
|
|
|
|
-* An allograft contains differnet genetic variants from the host,
|
|
|
- resulting in protein-coding differences
|
|
|
+* HLA genes encoding MHC proteins are highly polymorphic \vspace{10pt}
|
|
|
|
|
|
-* Left unchecked, the host immune system eventually notices these
|
|
|
- alloantigens and begins attacking (rejecting) the graft
|
|
|
+* Variants in donor MHC can trigger the same T-cell response as a
|
|
|
+ foreign antigen
|
|
|
|
|
|
-* Rejection is the major long-term threat to organ allografts
|
|
|
+\vspace*{36pt}
|
|
|
+
|
|
|
+\rule{\linewidth}{0pt}
|
|
|
+
|
|
|
+::::
|
|
|
|
|
|
:::
|
|
|
|
|
|
+::: {.column width="25%"}
|
|
|
+{ height=70% }
|
|
|
+:::
|
|
|
+
|
|
|
+:::::
|
|
|
+
|
|
|
+## Allograft rejection is a major long-term problem
|
|
|
+
|
|
|
+![Kidney allograft survival rates in children by transplant year[^kim-marks]](graphics/presentation/kidney-graft-survival.png){ height=65% }
|
|
|
+
|
|
|
+[^kim-marks]:[ Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884158/?report=classic)
|
|
|
+
|
|
|
## Rejection is treated with immune suppressive drugs
|
|
|
|
|
|
<!-- TODO: Need a graphic, or maybe a table of common drugs +
|
|
@@ -80,19 +96,19 @@ mechanisms, or a diagram for periodic checking. -->
|
|
|
|
|
|
::: incremental
|
|
|
|
|
|
-* To prevent rejection, a graft recipient must take immune suppressive
|
|
|
- drugs for the rest of their life
|
|
|
+* Graft recipient must take immune suppressive drugs indefinitely
|
|
|
|
|
|
-* The graft is periodically checked for signs of rejection, and immune
|
|
|
- suppression dosage is adjusted accordingly
|
|
|
+* Graft is monitored for rejection and dosage adjusted over time
|
|
|
+
|
|
|
+* Immune suppression is a delicate balance: too much and too little
|
|
|
+ are both problematic.
|
|
|
|
|
|
-* Immune suppression is a delicate balance: too much leads to immune
|
|
|
- compromise; too little leads to rejection.
|
|
|
-
|
|
|
:::
|
|
|
|
|
|
## My thesis topics
|
|
|
|
|
|
+<!-- Needs revision -->
|
|
|
+
|
|
|
### Topic 1: Immune memory
|
|
|
Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
|
|
|
and memory $\mathsf{CD4}^{+}$ T-cell activation
|